Tactile Systems Technology (TCMD)
NASDAQ:TCMD
Want to see TCMD full AI Analyst Report?
TCMD Stock Chart & Stats
$25.73
$0.01(0.06%)
At close: 4:00 PM EST
$25.73
$0.01(0.06%)
Day’s Range― - ―
52-Week Range$9.42 - $37.77
Previous CloseN/A
Volume58.88K
Average Volume (3M)279.13K
Market Cap
$600.45M
Enterprise Value$522.81M
Total Cash (Recent Filing)$74.99M
Total Debt (Recent Filing)$15.17M
Price to Earnings (P/E)29.6
Beta0.68
Next Earnings
Aug 10, 2026EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.90
Shares Outstanding22,556,260
10 Day Avg. Volume188,915
30 Day Avg. Volume279,135
Financial Highlights & Ratios
PEG Ratio2.07
Price to Book (P/B)3.03
Price to Sales (P/S)2.01
P/FCF Ratio16.41
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue1.52
Enterprise Value/Gross Profit2.01
Enterprise Value/Ebitda12.59
Forecast
1Y Price Target
$39.50Price Target Upside53.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.14
Revenue Forecast (FY)$364.81M
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageA very low debt-to-equity ratio and materially reduced leverage provide durable financial flexibility. With limited borrowings the company can fund product investment, M&A integration, and buybacks without stressing liquidity, lowering solvency risk through multiple business cycles.
Strong Cash Generation And ConversionConsistent operating and free cash flow near reported earnings supports reinvestment and strategic options. Healthy cash conversion and FCF provide a sustainable funding source for growth initiatives, working-capital demands, and integration costs over the coming 2–6 months.
Product, R&D And Tech MomentumRegulatory clearance for an improved, connected product plus continued R&D signals durable product differentiation. Next-gen devices and digital connectivity can raise adoption, support higher recurring consumable sales, and strengthen clinical value propositions versus legacy competitors.
Bears Say
Medicare Prior-authorization Regulatory RiskA structural change in reimbursement administration creates persistent execution risk. Variable MAC implementations and initial adjudication uncertainty can slow patient starts, extend cash collection cycles, and complicate forecasting until nationwide prior-authorization patterns stabilize.
Acquired Revenue Mix Includes Lower-margin Grants/servicesAdding Lymphotech expands addressable market but introduces lower-margin grant and service revenue that can structurally depress consolidated margins. Integration may shift revenue mix, requiring time and execution to convert to higher-margin recurring device and consumable sales.
Rising Operating Expense BaseSustained higher spend to support commercialization, tech and integration can pressure near-term operating leverage. If revenue cadence lags (eg. from prior-auth timing), elevated opex could compress margins and delay durable EBITDA expansion until productivity gains fully materialize.
Tactile Systems Technology News
TCMD FAQ
What was Tactile Systems Technology’s price range in the past 12 months?
Tactile Systems Technology lowest stock price was $9.41 and its highest was $37.77 in the past 12 months.
What is Tactile Systems Technology’s market cap?
Tactile Systems Technology’s market cap is $600.45M.
When is Tactile Systems Technology’s upcoming earnings report date?
Tactile Systems Technology’s upcoming earnings report date is Aug 10, 2026 which is in 45 days.
How were Tactile Systems Technology’s earnings last quarter?
Tactile Systems Technology released its earnings results on May 04, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.12 by $0.04.
Is Tactile Systems Technology overvalued?
According to Wall Street analysts Tactile Systems Technology’s price is currently Undervalued.
Does Tactile Systems Technology pay dividends?
Tactile Systems Technology does not currently pay dividends.
What is Tactile Systems Technology’s EPS estimate?
Tactile Systems Technology’s EPS estimate is 0.14.
How many shares outstanding does Tactile Systems Technology have?
Tactile Systems Technology has 22,556,260 shares outstanding.
What happened to Tactile Systems Technology’s price movement after its last earnings report?
Tactile Systems Technology reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.12. Following the earnings report the stock price went up 7.222%.
Which hedge fund is a major shareholder of Tactile Systems Technology?
Currently, no hedge funds are holding shares in TCMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tactile Systems Technology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.50 (53.52% Upside)
$39.50 (53.52% Upside)
Blogger Sentiment
Bullish
TCMD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 176.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $113.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
165.09%
12-Months-Change
Fundamentals
Return on Equity
9.70%
Trailing 12-Months
Asset Growth
-2.90%
Trailing 12-Months
Company Description
Tactile Systems Technology
Tactile Systems Technology, Inc. is a medical technology firm that develops and supplies specialized devices to treat chronic health conditions across the United States. Its product portfolio features the Flexitouch Plus system, a pneumatic compression device designed for managing lymphedema. The company also offers the Entre system, a portable pneumatic compression solution for at-home treatment of various venous disorders, including lymphedema, chronic venous insufficiency, and venous leg ulcers. Additionally, Tactile Systems provides the AffloVest, a portable high-frequency chest wall oscillation device used to address retained pulmonary secretions associated with conditions such as bronchiectasis, cystic fibrosis, and certain neuromuscular disorders. Established in 1995, the company maintains its headquarters in Minneapolis, Minnesota.
TCMD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call showed broad-based commercial strength (23% YoY revenue growth), margin expansion (gross margin +250 bps) and a turnaround to adjusted EBITDA profitability, supported by product clearances (next-gen AffloVest), AI deployment, and strategic M&A (Lymphotech). Management tempered near-term cadence expectations due to the new Medicare prior authorization process and flagged incremental expense and lower-margin grant revenue from the recent acquisition. On balance, operational and financial progress, upgraded guidance, and a strong product and innovation roadmap outweigh the manageable short-term execution and margin composition risks.View all TCMD earnings summariesTCMD Stock 12 Month Forecast
Average Price Target
$39.50
▲(53.52% Upside)
Technical Analysis
Sanuwave Health
―
Viemed Healthcare
―
Outset Medical
―
TriSalus Life Sciences
―
Ceribell, Inc.
―
Ownership Overview
3.57% Insiders
20.19% Mutual Funds
26.50% Other Institutional Investors
30.41% Public Companies and
Individual Investors